Samsung Bioepis and Teva sign up to $420 million U.S. biosimilar commercialization deal
+2 new sources since this summary was written
Samsung Bioepis and Teva Pharmaceutical have entered a license and commercialization agreement for two FDA‑approved biosimilars, Renflexis (infliximab‑abda) and Eticovo (etanercept‑ykro). Samsung Bioepis will develop, manufacture and supply the products, while Teva will handle U.S. sales. The contract is valued at up to $420 million, comprising an upfront payment of up to $75 million, launch milestones of up to $75 million and sales‑based milestones of up to $270 million, and is expected to close by the end of 2026.
Why it matters
The agreement expands Teva's immunology portfolio and provides a new revenue stream from upfront and milestone payments, which the company expects to receive over the next three years. The deal also gives Samsung Bioepis a sizable U.S. commercial partner, potentially boosting its future sales of the two biosimilars.
Key facts
- 1The partnership covers two biosimilars, Renflexis (infliximab‑abda) and Eticovo (etanercept‑ykro). biz.chosun.com
- 2The total deal value is up to $420 million. biz.chosun.com
- 3The upfront payment can be as high as $75 million, with $50 million payable within 30 days of the contract effective date. biz.chosun.com
- 4Launch‑related milestones are capped at $75 million and sales‑based milestones at $270 million. biz.chosun.com
- 5Teva will obtain U.S. commercialization rights to etanercept‑ykro at closing and to infliximab‑abda in Q3 2027. stocktitan.net
- 6The agreement is expected to close by the end of 2026, subject to customary regulatory approvals. stocktitan.net
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.